How have NRBO shares performed in 2024?

NeuroBo Pharmaceuticals' stock was trading at $3.70 at the start of the year. Since then, NRBO shares have decreased by 8.1% and is now trading at $3.40. View the best growth stocks for 2024 here .

When is NeuroBo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our NRBO earnings forecast .

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Monday, November, 15th. The company reported ($38.40) EPS for the quarter, topping the consensus estimate of ($43.20) by $4.80.

When did NeuroBo Pharmaceuticals' stock split?

NeuroBo Pharmaceuticals's stock reverse split on the morning of Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC) , Cumberland Pharmaceuticals (CPIX) , Akero Therapeutics (AKRO) , Chimerix (CMRX) , Trevena (TRVN) , VBI Vaccines (VBIV) , VIVUS (VVUS) and Aldeyra Therapeutics (ALDX) .

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NRBO

NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free NRBO Stock Alerts

$3.40

-0.06 (-1.73%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.35
▼
$3.63
50-Day Range: $3.40
▼
$6.52
52-Week Range: $2.89
▼
$6.75

Volume: 22,788 shs
Average Volume: 31,600 shs
Market Capitalization: $16.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get NeuroBo Pharmaceuticals alerts:

NeuroBo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.41
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.00) to ($1.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.84 out of 5 stars

Medical Sector

784th out of 918 stocks

Pharmaceutical Preparations Industry

361st out of 427 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for NeuroBo Pharmaceuticals.

5.0

Short Interest

Percentage of Shares Shorted
1.93% of the float of NeuroBo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
NeuroBo Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NeuroBo Pharmaceuticals has recently decreased by 9.50%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NeuroBo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
NeuroBo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NRBO.

2.5

News and Social Media Coverage

News Sentiment
NeuroBo Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for NeuroBo Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NRBO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.
MarketBeat Follows
1 people have added NeuroBo Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.79% of the stock of NeuroBo Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 1.37% of the stock of NeuroBo Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($3.00) to ($1.90) per share.
Price to Book Value per Share Ratio
NeuroBo Pharmaceuticals has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NRBO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRBO Stock News Headlines

April 19, 2024 | americanbankingnews.com

Head to Head Review: NeuroBo Pharmaceuticals (NASDAQ:NRBO) vs. Ainos (NASDAQ:AIMD)

April 17, 2024 | finance.yahoo.com

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

April 17, 2024 | prnewswire.com

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

April 5, 2024 | morningstar.com

NeuroBo Pharmaceuticals Inc NRBO

April 1, 2024 | prnewswire.com

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

March 28, 2024 | finanznachrichten.de

NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

March 28, 2024 | prnewswire.com

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

March 13, 2024 | markets.businessinsider.com

NeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%

March 13, 2024 | prnewswire.com

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

March 4, 2024 | finanznachrichten.de

NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

March 4, 2024 | msn.com

NeuroBo Pharmaceuticals appoints Marshall Woodworth as CFO

March 4, 2024 | markets.businessinsider.com

NeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFO

March 4, 2024 | finance.yahoo.com

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

February 29, 2024 | markets.businessinsider.com

NeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock Gains

February 29, 2024 | prnewswire.com

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

February 12, 2024 | finance.yahoo.com

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

February 6, 2024 | finance.yahoo.com

NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…

February 2, 2024 | msn.com

NeuroBo’s DA-1726 Obesity Therapy Gets FDA IND Approval

February 1, 2024 | msn.com

Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher

February 1, 2024 | markets.businessinsider.com

NeuroBo Pharma'a IND Application For DA-1726 Gets FDA Clearance

February 1, 2024 | markets.businessinsider.com

NeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726

February 1, 2024 | msn.com

NeuroBo to begin Phase 1 testing of potential Wegovy rival

February 1, 2024 | finance.yahoo.com

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

January 30, 2024 | investing.com

Neurobo Pharmaceuticals Inc (NRBO)

January 18, 2024 | markets.businessinsider.com

NeuroBo Announces Positive Pre-Clinical Safety Data Of DA-1241 In Combination With Sitagliptin

See More Headlines

Receive NRBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NRBO
CUSIP: N/A
CIK: 1638287
Web: www.neurobopharma.com
Phone: (857) 702-9600
Fax: 734-293-0444
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,470,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -59.42%
Return on Assets: -45.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.78
Quick Ratio: 3.78

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.44 per share
Price / Book: 0.99

Miscellaneous

Outstanding Shares: 4,910,000
Free Float: 4,867,000
Market Cap: $16.69 million
Optionable: Not Optionable
Beta: -0.25

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Hyung-Heon Kim (Age 49)
CEO, President, Principal Executive & Director
Comp: $54.22k
Mr. Marshall H. Woodworth (Age 66)
CFO, Principal Financial Officer & Principal Accounting Officer
Dr. Mi-Kyung Kim
Chief Scientific Officer
Mr. Robert Homolka
Senior Vice President of Clinical Operations

Key Competitors

View All Competitors

NRBO Stock Analysis - Frequently Asked Questions

How have NRBO shares performed in 2024?: NeuroBo Pharmaceuticals' stock was trading at $3.70 at the start of the year. Since then, NRBO shares have decreased by 8.1% and is now trading at $3.40.
View the best growth stocks for 2024 here.
When is NeuroBo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our NRBO earnings forecast.
How were NeuroBo Pharmaceuticals' earnings last quarter?: NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Monday, November, 15th. The company reported ($38.40) EPS for the quarter, topping the consensus estimate of ($43.20) by $4.80.
When did NeuroBo Pharmaceuticals' stock split?: NeuroBo Pharmaceuticals's stock reverse split on the morning of Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX).
How do I buy shares of NeuroBo Pharmaceuticals?: Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRBO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial